| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
AMD macular degenerationPegaptanibRanibizumabVEGFBevacizumabSunitinibSorafenib| 1 | 2008 | Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. | 
| + | - | nl | Health Technol Assess 12(16):iii-iv, ix-201 (2008) Colquitt JL |
| 2 | 2007 | A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). |
| + | - | nl | Indian J Ophthalmol 55(6):437-9 (2007) |
| 3 | 2007 | Role of ranibizumab in management of macular degeneration. |
| + | - | nl | Indian J Ophthalmol 55(6):421-5 (2007) |
| 4 | 2007 | Vascular endothelial growth factor: biology and therapeutic applications. |
| + | - | nl | Int J Biochem Cell Biol 39(7-8):1349-57 (2007) |
| 5 | 2011 | Ranibizumab and the eye. |
| + | - | nl | CMAJ 183(7):822 (2011) |
